Cargando…

Comparison of Abiraterone and Combined Androgen Blockade Therapy for High-Risk Metastatic Hormone-Sensitive Prostate Cancer: A Propensity Score-Matched Analysis

This study aimed to compare the effects of abiraterone acetate plus prednisone (AAP) with androgen deprivation therapy (ADT) with those of combined androgen blockade (CAB) therapy in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC). This study retrospectively identified 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsumura, Naoki, Fujita, Kazutoshi, Nishimoto, Mitsuhisa, Yamamoto, Yutaka, Kuwahara, Ken, Nagai, Yasuharu, Minami, Takafumi, Hatanaka, Yuji, Nozawa, Masahiro, Morimoto, Yasuhiro, Tahara, Hideo, Uejima, Shigeya, Esa, Atsunobu, Hirayama, Akihide, Yoshimura, Kazuhiro, Uemura, Hirotsugu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724311/ https://www.ncbi.nlm.nih.gov/pubmed/34993133 http://dx.doi.org/10.3389/fonc.2021.769068

Ejemplares similares

Sarcopenia and Visceral Obesity are Significantly Related to Severe Storage Symptoms in Geriatric Female Patients
por: Hashimoto, Mamoru, et al.
Publicado: (2021)

Serious Hypokalemia Associated with Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer
por: Yamamoto, Yutaka, et al.
Publicado: (2018)

Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide
por: Fujmoto, Saizo, et al.
Publicado: (2022)

Prognostic factors in Japanese men with high-Gleason metastatic castration-resistant prostate cancer
por: Nishimoto, Mitsuhisa, et al.
Publicado: (2022)

Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naïve metastatic prostate cancer patients – A propensity scoring approach
por: Nagao, Kazuhiro, et al.
Publicado: (2016)

A case of neuroendocrine tumor at the external urethral meatus after total cystectomy
por: Miki, Koji, et al.
Publicado: (2023)

Prognosis and safety of radium‐223 with concurrent abiraterone acetate or enzalutamide use for metastatic castration‐resistant prostate cancer: Real‐world data of Japanese patients
por: Miyoshi, Yasuhide, et al.
Publicado: (2020)

Clinical Outcome of Small Renal Cell Carcinoma after Delayed Surgery versus Immediate Surgery
por: Sugimoto, Koichi, et al.
Publicado: (2013)

Higher neutrophil-to-lymphocyte ratio after the first cycle of the first-line chemotherapy is associated with poor cancer specific survival of upper urinary tract carcinoma patients
por: Hashimoto, Mamoru, et al.
Publicado: (2021)

Acotiamide hydrochloride hydrate added to combination treatment with an α-blocker and a cholinergic drug improved the QOL of women with acute urinary retention: case series
por: Sugimoto, Koichi, et al.
Publicado: (2017)

Therapeutic efficacy and anti-inflammatory effect of ramelteon in patients with insomnia associated with lower urinary tract symptoms
por: Shimizu, Nobutaka, et al.
Publicado: (2013)

Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer
por: Yamamoto, Yutaka, et al.
Publicado: (2015)

Evaluation of biochemical recurrence in patients with high-risk prostate cancer treated with radical prostatectomy and radiotherapy plus androgen deprivation therapy
por: Yamamoto, Yutaka, et al.
Publicado: (2016)

Comparison of molecular profiles of upper tract urothelial carcinoma vs. urinary bladder cancer in the era of targeted therapy: a narrative review
por: Tomiyama, Eisuke, et al.
Publicado: (2022)

Survey on lower urinary tract symptoms and sleep disorders in patients treated at urology departments
por: Shimizu, Nobutaka, et al.
Publicado: (2013)

Trop-2 in Upper Tract Urothelial Carcinoma
por: Tomiyama, Eisuke, et al.
Publicado: (2022)

Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma
por: Yoshimura, K, et al.
Publicado: (2013)

The Gut-Prostate Axis: A New Perspective of Prostate Cancer Biology through the Gut Microbiome
por: Fujita, Kazutoshi, et al.
Publicado: (2023)

Abiraterone Acetate
Publicado: (2012)

Transfection of poly(I:C) can induce reactive oxygen species-triggered apoptosis and interferon-β-mediated growth arrest in human renal cell carcinoma cells via innate adjuvant receptors and the 2-5A system
por: Harashima, Nanae, et al.
Publicado: (2014)

A Phase 2 Trial of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer and without Prior Chemotherapy (JPN-201 Study)
por: Matsubara, Nobuaki, et al.
Publicado: (2014)

Clinical outcome of incidentally discovered small renal cell carcinoma after delayed surgery
por: Sugimoto, Koichi, et al.
Publicado: (2013)

Continuous or intermittent? On the dosing schedule of sunitinib for advanced renal cell carcinoma
por: Nozawa, Masahiro, et al.
Publicado: (2012)

Proposal of “cyclic therapy”, a novel treatment strategy with targeted agents for advanced renal cell carcinoma
por: Nozawa, Masahiro, et al.
Publicado: (2013)

Comparison of the Safety and Efficacy of Photoselective Vaporization of the Prostate (PVP) and Transurethral Enucleation with a Bipolar System (TUEB): A Single-Center Retrospective Study
por: Kiba, Keisuke, et al.
Publicado: (2020)

Low cost abiraterone
por: Barreiro, Diego Martin, et al.
Publicado: (2015)

Abiraterone-Induced Endocrinopathies
por: Decamps, Scarlett, et al.
Publicado: (2023)

Androgen dynamics and serum PSA in patients treated with abiraterone acetate
por: Ryan, C J, et al.
Publicado: (2014)

Efficacy of abiraterone acetate for high-risk hormone-naïve metastatic prostate cancer: A comparison with combined androgen blockade therapy with bicalutamide and androgen deprivation therapy alone
por: Kanao, Kent, et al.
Publicado: (2022)

Reactivation of latent tuberculosis infection induced by cabazitaxel in a patient with prostate cancer: A case report
por: Hashimoto, Mamoru, et al.
Publicado: (2019)

Abiraterone: moving up in line?
por: Strijbos, Michiel
Publicado: (2018)

A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer
por: Miyoshi, Yasuhide, et al.
Publicado: (2021)

Context-Specific Efficacy of Apalutamide Therapy in Preclinical Models of Pten-Deficient Prostate Cancer
por: De Velasco, Marco A., et al.
Publicado: (2021)

Abiraterone acetate, an inhibitor of adrenal androgen synthesis in “hormone refractory prostate cancer”
por: Goel, Arun Kumar, et al.
Publicado: (2011)

Abiraterone Acetate: Targeting Persistent Androgen Dependence in Castration-Resistant Prostate Cancer
por: Harshman, Lauren C., et al.
Publicado: (2013)

Redirecting abiraterone metabolism to fine tune prostate cancer anti-androgen therapy
por: Li, Zhenfei, et al.
Publicado: (2016)

Prognostic factors for patients treated with abiraterone
por: Alvim, Cecília M, et al.
Publicado: (2019)

Firmicutes in Gut Microbiota Correlate with Blood Testosterone Levels in Elderly Men
por: Matsushita, Makoto, et al.
Publicado: (2022)

Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2014)

A case of abiraterone acetate withdrawal syndrome after initiation of upfront abiraterone therapy for high‐risk prostate cancer
por: Tani, Masaru, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_70gmrv0ta2r0ghcdme8bq9gbkj